

VITAL BONE CAL/MAG/D3



Flourish

PHARMACY | NUTRITION

Clinical Applications

- Supports Bone Metabolism*
- Supports Bone Strength*
- Provides Micronutrients for Utilization in Bone Production and Structure*

*Ossopan is a well-researched, standardized extract from one of the world's safest premium sources of bone—free-range New Zealand cattle. Ossopan contains microcrystalline hydroxyapatite concentrate (MCHC), a complex crystalline compound composed primarily of calcium, phosphorus, bioactive growth factors, type I collagen, amino acids, glycosaminoglycans, and a broad range of essential trace elements that naturally comprise healthy bone. VITAL BONE CAL/MAG/D3 MD contains additional calcium and magnesium in the form of highly absorbable Albion® TRAACS® patented mineral amino acid chelates. Vitamin D is present in the form of cholecalciferol.**

All Flourish Pharmacy Formulas Meet or Exceed cGMP Quality Standards

Discussion

More than 20 years of scientific research have given the name Ossopan worldwide recognition as a source of microcrystalline hydroxyapatite concentrate (MCHC). Numerous published studies support the safety, tolerability, and bone health-related effectiveness of MCHC supplementation.^[1,2] Studies suggest that the bioavailability of calcium from MCHC supplements may be as good as or better than the bioavailability of calcium from calcium gluconate supplements.^[3,4] Flourish Pharmacy utilizes standardized, safe, bovine-sourced MCHC from New Zealand, a country with stringent standards. Its production features a proprietary technique that preserves the bioactive contents of bone. This process creates a naturally balanced formula because whole bone extract provides all of the nutrients found in healthy bone.*

VITAL BONE CAL/MAG/D3 MD incorporates Ossopan, vitamin D, magnesium, and additional calcium in a comprehensive formula. Vitamin D is provided as cholecalciferol, which stimulates intestinal calcium absorption and helps support calcium and phosphorus homeostasis in the body. The formula contains a desirable 2:1 ratio of calcium to magnesium. The malate chelates do not react with stomach acid and are less likely than carbonates to cause discomfort and acid rebound.*^[13]

***These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.**

Manufactured for: Flourish Pharmacy
14720 N. Pennsylvania Ave.
Oklahoma City, OK 73134
P: 405-751-3333
www.FlourishRx.com

VITAL BONE CAL/MAG/D3



VITAL BONE CAL/MAG/D3

Supplement Facts

Serving Size: 2 Capsules
Servings Per Container: 60

	Amount Per Serving	%Daily Value
Vitamin D3 (as cholecalciferol)	100 IU	25%
Calcium (as MCHC [†] and DimaCal [®] Di-Calcium Malate)	400 mg	40%
Phosphorus (as MCHC [†])	90 mg	9%
Magnesium (as Di-Magnesium Malate and TRAACS [®] Magnesium Glycinate Chelate Buffered)	200 mg	50%
MCHC [†]	1 g	**
Microcrystalline Hydroxyapatite (as MCHC [†])	600 mg	**

** Daily Value not established.

Other Ingredients: HPMC (capsule), vegetable stearic acid, vegetable magnesium stearate, medium-chain triglycerides, and silica.

[†]MicroCrystalline Hydroxyapatite Concentrate.

DimaCal and TRAACS are registered trademarks of Albion Laboratories, Inc. Malates covered by US Patent 6,706,904 and patents pending.

Supplement Facts

Serving Size: 2 Capsules
Servings Per Container: 120

	Amount Per Serving	%Daily Value
Vitamin D3 (as cholecalciferol)	100 IU	25%
Calcium (as MCHC [†] and DimaCal [®] Di-Calcium Malate)	400 mg	40%
Phosphorus (as MCHC [†])	90 mg	9%
Magnesium (as Di-Magnesium Malate and TRAACS [®] Magnesium Glycinate Chelate Buffered)	200 mg	50%
MCHC [†]	1 g	**
Microcrystalline Hydroxyapatite (as MCHC [†])	600 mg	**

** Daily Value not established.

Other Ingredients: HPMC (capsule), vegetable stearic acid, vegetable magnesium stearate, medium-chain triglycerides, and silica.

[†] MicroCrystalline Hydroxyapatite Concentrate.

DimaCal and TRAACS are registered trademarks of Albion Laboratories, Inc. Malates covered by US Patent 6,706,904 and patents pending.

Directions

Take two capsules with meals, twice daily, or as directed by your healthcare practitioner.

Children and pregnant or lactating women should consult their healthcare practitioner prior to use. Do not use if tamper seal is damaged.

Does Not Contain

Wheat, gluten, corn protein, yeast, soy, dairy products, fish, shellfish, peanuts, tree nuts, egg, artificial colors, artificial sweeteners, or preservatives.

References

1. Pines A, Raafat H, Lynn AH, et al. Clinical trial of microcrystalline hydroxyapatite compound ('Ossopan') in the prevention of osteoporosis due to corticosteroid therapy. *Curr Med Res Opin.* 1984;8(10):734-42. [PMID: 6373153]
2. Stellan A, Davies A, Webb A, et al. Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis. *Postgrad Med J.* 1985 Sep;61(719):791-6. [PMID: 2997764]
3. Buclin T, Jacquet AF, Burckhardt P. Intestinal absorption of calcium gluconate and ossein-mineral complex: an evaluation by conventional analyses [in French]. *Schweiz Med Wochenschr.* 1986 Dec 13;116(50):1780-3. [PMID: 3026039]
4. Epstein O, Kato Y, Dick R, et al. Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis. *Am J Clin Nutr.* 1982 Sep;36(3):426-30. [PMID: 6287835]
5. Stepan JJ, Mohan S, Jennings JC, et al. Quantitation of growth factors in ossein-mineral-compound. *Life Sci.* 1991;49(13):PL79-84. [PMID: 1653384]
6. Annefeld M, Caviezel R, Schacht E, et al. The influence of ossein-hydroxyapatite compound ('Ossopan') on the healing of a bone defect. *Curr Med Res Opin.* 1986;10(4):241-50. [PMID: 3022988]
7. Fernández-Pareja A, Hernández-Blanco E, Pérez-Maceda JM, et al. Prevention of osteoporosis: four-year follow-up of a cohort of postmenopausal women treated with an ossein-hydroxyapatite compound. *Clin Drug Investig.* 2007;27(4):227-32. [PMID: 17358094]
8. Rüeggsegger P, Keller A, Dambacher MA. Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females. *Osteoporos Int.* 1995 Jan;5(1):30-4. [PMID: 7703621]
9. Khadzhiev A, Rachev E, Katsarova M, Chervenishki S. The results of a clinical trial of the preparation Ossopan [in Bulgarian]. *Akush Ginekol (Sofia).* 1990;29(4):85-7. [PMID: 2176437]
10. Castelo-Branco C, Martínez de Osaba MJ, Pons F, et al. Ossein-hydroxyapatite compounds for preventing postmenopausal bone loss. Coadjuvant use with hormone replacement therapy. *J Reprod Med.* 1999 Mar;44(3):241-6. [PMID: 10202741]
11. Castelo-Branco C, Pons F, Vicente JJ, et al. Preventing postmenopausal bone loss with ossein-hydroxyapatite compounds. Results of a two-year, prospective trial. *J Reprod Med.* 1999 Jul;44(7):601-5. [PMID: 10442322]
12. Bovine Spongiform Encephalopathy Status of Members. OIE-World Organization for Animal Health Web site. <http://www.oie.int/animal-health-in-the-world/official-disease-status/bse/list-of-bse-risk-status/>. Accessed October 10, 2012.
13. Albion. Malic acid can be the right ligand for certain applications. Albion[®] Research Notes; April 2003;12(2). <http://www.albionhumannutrition.com/research-notes/download?start=40>. Accessed October 10, 2012.

***These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.**

Manufactured for: Flourish Pharmacy
14720 N. Pennsylvania Ave.
Oklahoma City, OK 73134
P: 405-751-3333
www.FlourishRx.com

DRS-111
REV. 120612